Cargando…

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse

BACKGROUND: Ibrutinib, an irreversible Bruton Tyrosine Kinase (BTK) inhibitor, has revolutionized Chronic Lymphocytic Leukemia (CLL) treatment, but resistances to ibrutinib have emerged, whether related or not to BTK mutations. Patterns of CLL evolution under ibrutinib therapy are well characterized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cadot, Sarah, Valle, Carine, Tosolini, Marie, Pont, Frederic, Largeaud, Laetitia, Laurent, Camille, Fournie, Jean Jacques, Ysebaert, Loic, Quillet-Mary, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724843/ https://www.ncbi.nlm.nih.gov/pubmed/33298182 http://dx.doi.org/10.1186/s40364-020-00253-w

Ejemplares similares

Lymphoma Heterogeneity Unraveled by Single-Cell Transcriptomics
por: Ysebaert, Loic, et al.
Publicado: (2021)

Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients
por: Boissard, F, et al.
Publicado: (2015)

Nurse-like cells promote CLL survival through LFA-3/CD2 interactions
por: Boissard, Frédéric, et al.
Publicado: (2016)

Phased differentiation of γδ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers
por: Cerapio, Juan-Pablo, et al.
Publicado: (2021)

Single-Cell Signature Explorer for comprehensive visualization of single cell signatures across scRNA-seq datasets
por: Pont, Frédéric, et al.
Publicado: (2019)

Single-Cell RNAseq Profiling of Human γδ T Lymphocytes in Virus-Related Cancers and COVID-19 Disease
por: Cerapio, Juan Pablo, et al.
Publicado: (2021)

Single-cell spatial explorer: easy exploration of spatial and multimodal transcriptomics
por: Pont, Frédéric, et al.
Publicado: (2023)

Cancer Stem Cells of Differentiated B-Cell Malignancies: Models and Consequences
por: Gross, Emilie, et al.
Publicado: (2011)

Several immune escape patterns in non-Hodgkin's lymphomas
por: Laurent, Camille, et al.
Publicado: (2015)

IL-10 Rescues CLL Survival through Repolarization of Inflammatory Nurse-like Cells
por: Domagala, Marcin, et al.
Publicado: (2021)

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment
por: Betrian, S, et al.
Publicado: (2016)

Nurse-like cells impact on disease progression in chronic lymphocytic leukemia
por: Boissard, F, et al.
Publicado: (2016)

Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients
por: Protin, Caroline, et al.
Publicado: (2019)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
por: Series, Jennifer, et al.
Publicado: (2019)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

An agent-based model of monocyte differentiation into tumour-associated macrophages in chronic lymphocytic leukemia
por: Verstraete, Nina, et al.
Publicado: (2023)

Progressive multifocal leukoencephalopathy in a patient with relapsed chronic lymphocytic leukemia treated with Ibrutinib
por: Teixeira, Larissa Lane Cardoso, et al.
Publicado: (2022)

DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status
por: Grgurevic, Srdana, et al.
Publicado: (2018)

PTMselect: optimization of protein modifications discovery by mass spectrometry
por: Perchey, Renaud T., et al.
Publicado: (2019)

CITED2 affects leukemic cell survival by interfering with p53 activation
por: Mattes, Katharina, et al.
Publicado: (2017)

“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”
por: Cavallari, Maurizio, et al.
Publicado: (2017)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
por: Ferrarini, Isacco, et al.
Publicado: (2022)

The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells
por: Secchiero, Paola, et al.
Publicado: (2017)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
por: Hansson, Lotta, et al.
Publicado: (2017)

Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data
por: Le Louedec, Félicien, et al.
Publicado: (2021)

Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
por: Ysebaert, L, et al.
Publicado: (2015)

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
por: Fraser, G., et al.
Publicado: (2018)

Stress Granules in the Post-transcriptional Regulation of Immune Cells
por: Curdy, Nicolas, et al.
Publicado: (2021)

A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
por: Pooler, Darcy B., et al.
Publicado: (2022)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019)

Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib
por: Koba, Yusuke, et al.
Publicado: (2023)

Comprehensive benchmarking of CITE-seq versus DOGMA-seq single cell multimodal omics
por: Xu, Zhongli, et al.
Publicado: (2022)

Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study
por: Huang, Xiaojun, et al.
Publicado: (2018)

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
por: Hillmen, Peter, et al.
Publicado: (2023)

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia
por: Gauthier, Martin, et al.
Publicado: (2019)

Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis
por: Nuttall, Elisabeth, et al.
Publicado: (2019)

PB1879: OVERALL SURVIVAL OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB IN ALBANIA (2018-2022)
por: Calliku, E., et al.
Publicado: (2022)

Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias
por: Nikitin, Eugene, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hl0f32un1cb6pcvpoajft40jou